glp 1 agonist australia The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025 Timeline of SGLT2i and GLP-1RA

Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated superior efficacy for weight reduction and improved metabolic health compared with single GLP-1 agonists

The SURMOUNT-4 randomized clinical trial assessed the effect of tirzepatide discontinuation on the maintenance of weight reduction in adults with obesity and a weight-related complication, excluding diabetes

Bottom Line Noom Med stands out as a potential option for those who know they need more than just weekly injections

Too Little Food, Too Much Water For most people, drink more water is sound health advice and a smart way to tackle dizziness or headaches